Ocular mucous membrane pemphigoid Skin and Connective Tissue Diseases Bullous disorders
Conditions
Interventions
Intervention:
Intravenous methylprednisolone therapy 1 g in 250 ml of 0.9% saline daily administered over 30 minutes for three consecutive days, followed by a 6-233k tapering course of oral prednisol
Sponsors
Moorfields Eye Hospital NHS Foundation Trust (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with clinical features consistent with ocular mucous membrane pemphigoid 2. Patients with bilateral or unilateral ?moderate? (grade 3) or ?severe? (grade 4) ocular inflammation, with or without limbitis (i.e. oedema and increased vascularity along the limbus) 3. Patients may already be receiving non-cyclophosphamide immunosuppression
Exclusion criteria
Exclusion criteria: 1. Patients currently receiving cyclophosphamide 2. Patients with other causes of progressive conjunctival scarring (drug-induced pemphigoid with negative direct immunofluorescence biopsy, atopic keratoconjunctivitis, Sjogren?s syndrome, Stevens Johnson syndrome, chemical injury) 3. Active secondary malignancy 4. HIuman immunodeficiency virus (HIV) infection 5. Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of eyes achieving control of inflammation to grade 0 (nil) or grade 1 (minimal) at six weeks. This disease is not symmetric and responses between eyes can be very different. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving, at six weeks, a four-fold reduction in titre of circulating antibasement membrane antibodies. | — |
Countries
United Kingdom
Outcome results
None listed